CoChat

Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?

Open access
Bozzatello, Paola, Rocca, Paola, Mantelli, Emanuela, Bellino, Silvio · 2019 · International Journal of Molecular Sciences
Cited by 73

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

In the central nervous system omega-3 fatty acids modulate cell signaling and affect dopaminergic and serotonergic pathways. On this basis, a new application for omega-3 fatty acids has been proposed, concerning the treatment of several psychiatric disorders. The present article is an update of a previous systematic review and is aimed to provide a complete report of data published in the period between 1980 and 2019 on efficacy and tolerability of omega-3 fatty acids in psychiatric disorders. In July 2019, an electronic search on PUBMED, Medline and PsychINFO of all RCTs, systematic reviews and meta-analyses on omega-3 fatty acids and psychiatric disorders without any filter or MESH restriction was performed. After eligibility processes, the final number of records included in this review was 126. One hundred and two of these studies were RCTs, while 24 were reviews and meta-analyses. The role of omega-3 fatty acids was studied in schizophrenia, major depression, bipolar disorder, anxiety disorders, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, eating disorders, substance use disorder and borderline personality disorder. The main evidence of the efficacy of omega-3 fatty acids has been obtained in treating depressive symptoms in patients with major depression and, to a lesser degree, bipolar depression. Some efficacy was also found in early phases of schizophrenia in addition to antipsychotic treatment, but not in the chronic phases of psychosis. Small beneficial effects of omega-3 fatty acids were observed in ADHD and positive results were reported in a few trials on core symptoms of borderline personality disorder. For other psychiatric disorders results are inconsistent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms20215257

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 170

  1. Pusceddu, 2016, The Omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA) reverses corticosterone-induced changes in cortical neurons, Int. J. Neuropsychopharmacol., 6, 1
  2. Calder, 2017, Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition, Ageing Res. Rev., 40, 95, 10.1016/j.arr.2017.09.001 · DOI · Paper page
  3. Lapuente, 2019, Clinical advances in immunonutrition and atherosclerosis: A review, Front. Immunol., 10, 837, 10.3389/fimmu.2019.00837 · DOI
  4. Simopoulos, 1999, Essential fatty acids in health and chronic disease, Am. J. Clin. Nutr., 70, 560, 10.1093/ajcn/70.3.560s · DOI · Paper page
  5. Ergas, 2002, n-3 fatty acids and the immune system in autoimmunity, Isr. Med. Assoc. J., 4, 34
  6. Saunders, 2016, Omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: A review of biomarker and treatment studies, J. Clin. Psychiatry, 77, 1301, 10.4088/JCP.15r09925 · DOI
  7. Innis, 1999, Docosahexanoic and arachidonic acid prevent a decrease in dopaminergic and serotoninergic neurotrasmitters in frontal cortex caused by a linoleic and alpha-linoleic acid deficient diet in formula-fed piglets, J. Nutr., 129, 2088, 10.1093/jn/129.11.2088 · DOI · Paper page
  8. Sinn, 2010, Oiling the brain: A review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan, Nutrients, 2, 128, 10.3390/nu2020128 · DOI · Paper page
  9. Bozzatello, P., Brignolo, E., De Grandi, E., and Bellino, S. (2016). Supplementation with omega-3 fatty acids in psychiatric disorders: A review of literature data. J. Clin. Med., 5. · DOI · Paper page
  10. Mischoulon, 2013, Omega-3 fatty acids in psychiatry, Psychiatr. Clin. N. Am., 36, 15, 10.1016/j.psc.2012.12.002 · DOI · Paper page
  11. Glen, 1994, A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases, Schizophr. Res., 12, 53, 10.1016/0920-9964(94)90084-1 · DOI · Paper page
  12. Reddy, 2004, Reduced red blood cell membrane essential polyunsatu- rated fatty acids in first episode schizophrenia at neuroleptic-naive baseline, Schizophr. Bull., 30, 901, 10.1093/oxfordjournals.schbul.a007140 · DOI · Paper page
  13. Amminger, 2014, Polyunsaturated fatty acids in emerging psychosis: A safer alternative?, Early Interv. Psychiatry, 8, 199, 10.1111/eip.12151 · DOI
  14. Cadenhead, 2019, Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium, Schizophr. Res., 204, 96, 10.1016/j.schres.2018.09.022 · DOI · Paper page
  15. Sethom, 2010, Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia, Prostaglandins Leukot. Essent. Fat. Acids, 83, 131, 10.1016/j.plefa.2010.07.001 · DOI
  16. Sumiyoshi, 2011, Membrane fatty acid levels as a predictor of treatment response in chronic schizophrenia, Psychiatry Res., 186, 23, 10.1016/j.psychres.2010.07.049 · DOI
  17. Amminger, 2013, Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: A post hoc subgroup analysis of a double-blind, randomized controlled trial, Can. J. Psychiatry, 58, 402, 10.1177/070674371305800705 · DOI · Paper page
  18. Smesny, 2014, Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis, Mol. Psychiatry, 19, 317, 10.1038/mp.2013.7 · DOI · Paper page
  19. Berger, 2007, Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial, J. Clin. Psychiatry, 68, 1867, 10.4088/JCP.v68n1206 · DOI · Paper page
  20. Berger, 2008, Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study, Neuropsychopharmacology, 33, 2467, 10.1038/sj.npp.1301628 · DOI
  21. Wood, 2010, Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study, Psychiatry Res. Neuroimaging, 182, 180, 10.1016/j.pscychresns.2009.12.003 · DOI
  22. Emsley, 2014, A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia, Schizophr. Res., 158, 230, 10.1016/j.schres.2014.06.004 · DOI
  23. Trafalska, 2016, A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia, J. Psychiatr. Res., 73, 34, 10.1016/j.jpsychires.2015.11.013 · DOI
  24. Pawelczyk, 2017, Oxidative stress reduction related to the efficacy of n-3 polyunsaturated fatty acids in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized trial, Prostaglandins Leukot. Essent. Fat. Acids, 121, 7, 10.1016/j.plefa.2017.05.004 · DOI
  25. Pawelczyk, 2018, Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized clinical trial, Prog. Neuropsychopharm. Biol. Psychiatry, 83, 142, 10.1016/j.pnpbp.2017.12.008 · DOI
  26. Peet, 2002, A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms, J. Psychiat. Res., 36, 7, 10.1016/S0022-3956(01)00048-6 · DOI · Paper page
  27. Emsley, 2002, Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia, Am. J. Psychiatry, 159, 1596, 10.1176/appi.ajp.159.9.1596 · DOI · Paper page
  28. Emsley, 2006, The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial, Schizophr. Res., 84, 112, 10.1016/j.schres.2006.03.023 · DOI
  29. Jamilian, 2014, Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia, Glob. J. Health Sci., 18, 103
  30. Fenton, 2001, A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia, Am. J. Psychiatry, 158, 2071, 10.1176/appi.ajp.158.12.2071 · DOI · Paper page
  31. Robinson, 2019, Predictors of hospitalization of individuals with first-episode psychosis: Data from a 2-year follow-up of the raise-ETP, Psychiatr. Serv., 7, 569, 10.1176/appi.ps.201800511 · DOI
  32. Joy, 2006, Polyunsaturated fatty acid supplementation for schizophrenia, Cochrane Database Syst. Rev., 19, CD001257
  33. Berger, 2012, Eicosapentaenoic acid interventions in schizophrenia: Meta-analysis of randomized, placebo-controlled studies, J. Clin. Psychopharmacol., 32, 179, 10.1097/JCP.0b013e318248b7bb · DOI · Paper page
  34. Akter, 2012, A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia, J. Clin. Pharm. Ther., 37, 132, 10.1111/j.1365-2710.2011.01265.x · DOI
  35. Agostoni, C., Nobile, M., Ciappolino, V., Delvecchio, G., Tesei, A., Turolo, S., Crippa, A., Mazzocchi, A., Altamura, C.A., and Brambilla, P. (2017). The Role of omega-3 fatty acids in developmental psychopathology: A systematic review on early psychosis, Autism, and ADHD. Int. J. Mol. Sci., 18. · DOI · Paper page
  36. Carney, 2018, Nutritional deficiencies and clinical correlates in first-episode psychosis: A systematic review and meta-analysis, Schizophr. Bull., 44, 1275, 10.1093/schbul/sbx162 · DOI · Paper page
  37. 2017, Nutritional supplements in psychotic disorders, Actas Esp. Psiquiatr., 45, 16
  38. Peet, 1998, Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients, Biol. Psychiatry, 43, 315, 10.1016/S0006-3223(97)00206-0 · DOI · Paper page
  39. Chrysohoou, 2010, Fish consumption moderates depressive symptomatology in elderly men and women from the IKARIA study, Cardiol. Res. Pr., 2011, 219578
  40. Hoffmire, 2012, Associations between omega-3 poly-unsaturated fatty acids from fish consumption and severity of depressive symptoms: An analysis of the 2005–2008 national health and nutrition examination survey, Prostaglandins Leukot. Essent. Fat. Acids, 86, 155, 10.1016/j.plefa.2012.03.003 · DOI
  41. Beydoun, 2013, Ω−3 fatty acid intakes are inversely related to elevated depressive symptoms among United States women, J. Nutr., 143, 1743, 10.3945/jn.113.179119 · DOI
  42. Song, 2013, Essential fatty acids as potential anti-inflammatory agents in the treatment of affective disorders, Mod. Trends Pharmacopsychiatr., 28, 75, 10.1159/000343970 · DOI
  43. Lotrich, 2015, Inflammatory cytokine-associated depression, Brain Res., 1617, 113, 10.1016/j.brainres.2014.06.032 · DOI · Paper page
  44. Song, 2016, The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzheimer’s disease: Acting separately or synergistically?, Prog. Lipid Res., 62, 41, 10.1016/j.plipres.2015.12.003 · DOI · Paper page
  45. Chhetry, 2016, Omega-3 polyunsaturated fatty acid supplementation and white matter changes in major depression, J. Psychiatr. Res., 75, 65, 10.1016/j.jpsychires.2015.12.007 · DOI
  46. Peet, 2002, A dose-ranging study of the effects of ethyl- eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs, Arch. Gen. Psychiatry, 59, 913, 10.1001/archpsyc.59.10.913 · DOI · Paper page
  47. Llorente, 2003, Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing, Am. J. Obs. Gynecol., 188, 1348, 10.1067/mob.2003.275 · DOI · Paper page
  48. Marangell, 2003, A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression, Am. J. Psychiatry, 160, 996, 10.1176/appi.ajp.160.5.996 · DOI · Paper page
  49. Su, 2003, Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial, Eur. Neuropsychopharmacol., 13, 267, 10.1016/S0924-977X(03)00032-4 · DOI · Paper page
  50. Silvers, 2005, Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression, Prostaglandins Leukot. Ess. Fat. Acids, 72, 211, 10.1016/j.plefa.2004.11.004 · DOI · Paper page
  51. Nemets, 2006, Omega-3 treatment of childhood depression: A controlled, double-blind pilot study, Am. J. Psychiatry, 163, 1098, 10.1176/ajp.2006.163.6.1098 · DOI · Paper page
  52. Grenyer, 2007, Fish oil supplementation in the treatment of major depression: A randomised double- blind placebo-controlled trial. Prog, Neuropsychopharmacol. Biol. Psychiatry, 31, 1393, 10.1016/j.pnpbp.2007.06.004 · DOI
  53. Jazayeri, 2008, Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder, Aust. N. Z. J. Psychiatry, 42, 192, 10.1080/00048670701827275 · DOI · Paper page
  54. Lucas, 2009, Ethyleicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle- aged women: A double-blind, placebo-controlled, randomized clinical trial, Am. J. Clin. Nutr., 89, 641, 10.3945/ajcn.2008.26749 · DOI
  55. Mischoulon, 2009, A double-blind, randomized controlled trial of ethyl- eicosapentaenoate for major depressive disorder, J. Clin. Psychiatry, 70, 1636, 10.4088/JCP.08m04603 · DOI · Paper page
  56. Rondanelli, 2010, Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: A double-blind, placebo-controlled, randomized clinical trial, J. Am. Coll. Nutr., 29, 55, 10.1080/07315724.2010.10719817 · DOI · Paper page
  57. Rondanelli, 2011, Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: Effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life, J. Nutr. Health Aging, 15, 37, 10.1007/s12603-011-0011-y · DOI · Paper page
  58. Turecki, 2011, The efficacy of omega-3 supplementation for major depression: A randomized controlled trial, J. Clin. Psychiatry, 72, 1054, 10.4088/JCP.10m05966blu · DOI · Paper page
  59. Tajalizadekhoob, 2011, The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: A double-blind, randomized, placebocontrolled study, Eur. Arch. Psychiatry Clin. Neurosci., 261, 539, 10.1007/s00406-011-0191-9 · DOI
  60. Krawczyk, 2012, Augmentation of antidepressants with unsaturated fatty acids omega-3 in drug-resistant depression, Psychiatr. Pol., 46, 585
  61. Rizzo, 2012, Comparison between the AA/EPA ratio in depressed and non depressed elderly females: Omega-3 fatty acid supplementation correlates with improved symptoms but does not change immunological parameters, Nutr. J., 11, 82, 10.1186/1475-2891-11-82 · DOI · Paper page
  62. Karamati, 2013, Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: A randomized, doubleblind, placebo-controlled trial, Eur. Neuropsychopharmacol., 23, 636, 10.1016/j.euroneuro.2012.08.003 · DOI
  63. Mozurkewich, 2013, The mothers, Omega-3, and mental health study: A double-blind, randomized controlled trial, Am. J. Obs. Gynecol., 313, 1
  64. Judge, 2014, Pilot trial evaluating maternal docosahexaenoic acid consumption during pregnancy: Decreased postpartum depressive symptomatology, Int. J. Nursing Sci., 1, 339, 10.1016/j.ijnss.2014.10.005 · DOI
  65. Ginty, 2015, Short-term supplementation of acute long-chain omega-3 polyunsaturated fatty acids may alter depression status and decrease symptomology among young adults with depression: A preliminary randomized and placebo controlled trial, Psychiatry Res., 229, 485, 10.1016/j.psychres.2015.05.072 · DOI
  66. Mischoulon, 2015, A double-blind, randomized controlled clinical trial comparing eicosapentaenoic acid versus docosahexaenoic acid for depression, J. Clin. Psychiat., 76, 54, 10.4088/JCP.14m08986 · DOI · Paper page
  67. Park, 2015, Supplementation of n-3 polyunsaturated fatty acids for major depressive disorder: A randomized, double-blind, 12-week, placebo-controlled trial in Korea, Ann. Nutr. Metab., 66, 141, 10.1159/000377640 · DOI · Paper page
  68. Young, 2017, Psychoeducational psychotherapy and omega-3 supplementation improve co-occurring behavioral problems in youth with depression: Results from a pilot RCT, J. Abnorm. Child. Psychol., 45, 1025, 10.1007/s10802-016-0203-3 · DOI
  69. Gabbay, 2018, A Double-blind placebo-controlled trial of omega-3 fatty acids as a monotherapy for adolescent depression, J. Clin. Psychiatry, 26, 79
  70. Hsu, 2018, Omega-3 polyunsaturated fatty acid supplementation in prevention and treatment of maternal depression: Putative mechanism and recommendation, J. Affect. Disord., 238, 47, 10.1016/j.jad.2018.05.018 · DOI
  71. Jahangard, 2018, Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders—Results from a double-blind, randomized and placebo-controlled clinical trial, J. Psychiatr Res., 107, 48, 10.1016/j.jpsychires.2018.09.016 · DOI · Paper page
  72. Tayama, 2019, Omega-3 polyunsaturated fatty acids and psychological intervention for workers with mild to moderate depression: A double-blind randomized controlled trial, J. Affect. Disord., 245, 364, 10.1016/j.jad.2018.11.039 · DOI
  73. Rapaport, 2016, Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder a proof-of-concept study, Mol. Psychiatry, 21, 71, 10.1038/mp.2015.22 · DOI · Paper page
  74. Bloch, 2012, Omega-3 fatty acids for the treatment of depression: Systematic review and meta-analysis, Mol. Psychiatry, 17, 1272, 10.1038/mp.2011.100 · DOI · Paper page
  75. Appleton, 2015, Omega-3 fatty acids for depression in adults, Cochrane Database Syst. Rev., 11, CD004692
  76. Sublette, 2014, Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder, Int. J. Neuropsychopharmacol., 17, 383, 10.1017/S1461145713001399 · DOI · Paper page
  77. Sarris, 2010, Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines, J. Psychiatr. Res., 44, 32, 10.1016/j.jpsychires.2009.06.003 · DOI
  78. Rocha, 2012, High dietary ratio of omega-6 to omega-3 polyunsaturated acids during pregnancy and prevalence of post-partum depression, Matern. Child. Nutr., 8, 36, 10.1111/j.1740-8709.2010.00256.x · DOI · Paper page
  79. Appleton, 2016, ω-3 Fatty acids for major depressive disorder in adults: An abridged Cochrane review, BMJ Open, 6, e010172, 10.1136/bmjopen-2015-010172 · DOI · Paper page
  80. Hallahan, 2016, Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression, Br. J. Psychiatry, 209, 192, 10.1192/bjp.bp.114.160242 · DOI · Paper page
  81. Mocking, 2016, Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder, Transl. Psychiatry, 6, e756, 10.1038/tp.2016.29 · DOI · Paper page
  82. Schefft, 2017, Efficacy of adding nutritional supplements in unipolar depression: A systematic review and meta-analysis, Eur. Neuropsychopharmacol., 27, 1090, 10.1016/j.euroneuro.2017.07.004 · DOI
  83. Ciappolino, 2017, The role of n-3 polyunsaturated fatty acids (n-3PUFAs) in affective disorders, J. Affect. Disord., 224, 32, 10.1016/j.jad.2016.12.034 · DOI
  84. Martins, 2009, EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acids supplementation in depression evidence from a meta-analysis of randomized controlled trials, J. Am. Coll. Nutr., 28, 525, 10.1080/07315724.2009.10719785 · DOI · Paper page
  85. Sublette, 2011, Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression, J. Clin. Psychiatry, 72, 1577, 10.4088/JCP.10m06634 · DOI · Paper page
  86. Rutkofsky, 2017, The Psychoneuroimmunological role of omega-3 polyunsaturated fatty acids in major depressive disorder and bipolar disorder, Adv. Mind Body Med., 31, 8
  87. Chiu, 2005, Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder, J. Clin. Psychiatry, 66, 1613, 10.4088/JCP.v66n1219b · DOI · Paper page
  88. McNamara, 2008, Deficits in docosahexaenoic acid and associated elevations in the metabolism of arachidonic acid and saturated fatty acids in the postmortem orbitofrontal cortex of patients with bipolar disorder, Psychiatry Res., 160, 285, 10.1016/j.psychres.2007.08.021 · DOI · Paper page
  89. Hirashima, 2019, Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder, Am. J. Psychiatry, 161, 1922, 10.1176/ajp.161.10.1922 · DOI · Paper page
  90. Murphy, 2012, Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: A double-blind, randomized add-on clinical trial, J. Clin. Psychopharmacol., 32, 699, 10.1097/JCP.0b013e318266854c · DOI · Paper page
  91. Gracious, 2010, Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder, Bipolar Disord., 12, 142, 10.1111/j.1399-5618.2010.00799.x · DOI
  92. Turnbull, 2008, Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: A systematic review, Arch. Psychiat. Nurs., 22, 305, 10.1016/j.apnu.2008.02.011 · DOI
  93. Montgomery, 2008, Omega-3 fatty acids for bipolar disorder, Cochrane Database Syst. Rev., 2, CD005169
  94. Kraguljac, 2009, Efficacy of omega-3 fatty acids in mood disorders—A systematic review and metaanalysis, Psychopharmacol. Bull., 42, 39
  95. Polokowski, 2018, Omega-3 fatty acids and anxiety: A systematic review of the possible mechanisms at play, Nutr. Neurosci., 28, 1
  96. Thesing, 2018, Omega-3 polyunsaturated fatty acid levels and dysregulations in biological stress systems, Psychoneuroendocrinology, 97, 206, 10.1016/j.psyneuen.2018.07.002 · DOI
  97. Branchey, 2006, n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers, J. Clin. Psychopharmacol., 26, 661, 10.1097/01.jcp.0000246214.49271.f1 · DOI · Paper page
  98. Su, 2018, Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms: A Systematic Review and Meta-analysis, JAMA Netw. Open., 1, e182327, 10.1001/jamanetworkopen.2018.2327 · DOI · Paper page
  99. Fux, 2004, A placebo-controlled cross-over trial of adjunctive EPA in OCD, J. Psychiatr. Res., 38, 323, 10.1016/S0022-3956(03)00077-3 · DOI
  100. Matsuoka, 2015, Docosahexaenoic acid for selective prevention of posttraumatic stress disorder among severely injured patients: A randomized, placebo-controlled trial, J. Clin. Psychiatry, 76, e1015-22, 10.4088/JCP.14m09260 · DOI
  101. Matsuoka, 2016, Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega3 supplements, J. Affect. Disord., 205, 289, 10.1016/j.jad.2016.08.005 · DOI
  102. Matsumura, 2017, Effects of omega-3 polyunsaturated fatty acids on psychophysiological symptoms of post-traumatic stress disorder in accident survivors: A randomized, double-blind, placebo-controlledtrial, J. Affect. Disord., 224, 27, 10.1016/j.jad.2016.05.054 · DOI
  103. Branchey, 2008, Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers, Prog. Neuropsychopharmacol. Biol. Psychiatry, 32, 568, 10.1016/j.pnpbp.2007.10.020 · DOI
  104. Mocking, 2016, Fatty acid concentrations in patients with posttraumatic stress disorder compared to healthy controls, J. Affect. Disord., 205, 351, 10.1016/j.jad.2016.08.021 · DOI
  105. Alquraan, L., Alzoubi, K.H., Hammad, H., Rababa’h, S.Y., and Mayyas, F. (2019). Omega-3 fatty acids prevent post-traumatic stress disorder-induced memory impairment. Biomolecules, 9. · DOI
  106. Beltz, 2007, Omega-3 fatty acids upregulate adult neurogenesis, Neurosci. Lett., 415, 154, 10.1016/j.neulet.2007.01.010 · DOI · Paper page
  107. Calderon, 2004, Docosahexaenoic acid promotes neurite growth in hippocampal neurons, J. Neurochem., 90, 979, 10.1111/j.1471-4159.2004.02520.x · DOI · Paper page
  108. Kitamura, 2009, Adult neurogenesis modulates the hippocampus-dependent period of associative fear memory, Cell, 139, 814, 10.1016/j.cell.2009.10.020 · DOI · Paper page
  109. Matsuoka, Y., Nishi, D., Nakaya, N., Sone, T., Hamazaki, K., Hamazaki, T., and Koido, Y. (2011). Attenuating posttraumatic distress with omega-3 polyunsaturated fatty acids among disaster medical assistance team members after the Great East Japan Earthquake: The APOP randomized controlled trial. BMC Psychiatry, 11. · DOI
  110. Ginty, 2012, Preliminary evidence that acute long-chain omega-3 supplementation reduces cardiovascular reactivity to mental stress: A randomized and placebo controlled trial, Biol. Psychol., 89, 269, 10.1016/j.biopsycho.2011.09.012 · DOI
  111. Hamazaki, 2005, Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: A randomized, placebo-controlled, double-blind trial, Nutrition, 21, 705, 10.1016/j.nut.2004.07.020 · DOI
  112. Matsumura, 2012, The effect of omega-3 fatty acids on psychophysiological assessment for the secondary prevention of posttraumatic stress disorder: An open-label pilot study, Glob. J. Health Sci., 4, 3
  113. Spence, 2003, The effect of flax seed cultivars with differing content of alpha-linolenic acid and lignans on responses to mental stress, J. Am. Coll. Nutr., 22, 494, 10.1080/07315724.2003.10719327 · DOI
  114. Song, 2003, Effects of dietary n-3 or n6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats, J. Lipid Res., 44, 1984, 10.1194/jlr.M300217-JLR200 · DOI · Paper page
  115. Stevens, 1995, Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder, Am. J. Clin. Nutr., 62, 761, 10.1093/ajcn/62.4.761 · DOI · Paper page
  116. Bonvicini, 2016, Attention-deficit hyperactivity disorder in adults: A systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies, Mol. Psychiatry, 21, 872, 10.1038/mp.2016.74 · DOI · Paper page
  117. Martins, 2019, The role of marine omega-3 in human neurodevelopment, including autism spectrum disorders and attention-deficit/hyperactivity disorder—a review, Crit. Rev. Food Sci. Nutr., 18, 1
  118. Voigt, 2001, A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder, J. Pediatr., 139, 189, 10.1067/mpd.2001.116050 · DOI · Paper page
  119. Richardson, 2002, A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties, Prog. Neuropsychopharmacol. Biol. Psychiatry, 26, 233, 10.1016/S0278-5846(01)00254-8 · DOI · Paper page
  120. Stevens, 2003, EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors, Lipids, 38, 1007, 10.1007/s11745-006-1155-0 · DOI · Paper page
  121. Hirayama, 2004, Effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder—A placebo-controlled double-blind study, Eur. J. Clin. Nutr., 58, 467, 10.1038/sj.ejcn.1601830 · DOI · Paper page
  122. Sinn, 2008, Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: A randomised controlled trial, Prostaglandins Leukort. Essent. Fat. Acids, 78, 311, 10.1016/j.plefa.2008.04.004 · DOI
  123. Vanasse, 2009, Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized, double-blind, placebo-controlled study, Paediatr. Child. Health, 14, 89, 10.1093/pch/14.2.89 · DOI · Paper page
  124. Gustafsson, 2010, EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD, Acta Paediatr., 99, 1540, 10.1111/j.1651-2227.2010.01871.x · DOI · Paper page
  125. Perera, 2012, Combined !3 and !6 supplementation in children with attention-deficit hyperactivity disorder (ADHD) refractory to methylphenidate treatment, J. Child. Neurol., 27, 747, 10.1177/0883073811435243 · DOI · Paper page
  126. Manor, 2012, The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an open-label extension, Eur. Psychiatry, 27, 335, 10.1016/j.eurpsy.2011.05.004 · DOI · Paper page
  127. Milte, 2011, Polyunsaturated fatty acids, cognition and literacy in children with ADHD with and without learning difficulties, J. Child. Health Care, 15, 299, 10.1177/1367493511403953 · DOI · Paper page
  128. Gillies, 2012, Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents, Cochrane Database Syst. Rev., 7, CD007986
  129. Gow, 2015, Current evidence and future directions for research with omega-3 fatty acids and attention deficit hyperactivity disorder, Curr. Opin. Clin. Nutr. Metab. Care, 18, 133, 10.1097/MCO.0000000000000140 · DOI
  130. Bell, 2000, Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: A characteristic abnormality in neurodevelopmental disorders?, Prostaglandins Leukort. Essent. Fat. Acids, 63, 21, 10.1054/plef.2000.0186 · DOI
  131. Bell, 2004, Essential fatty acids and phospholipase A2 in autistic spectrum disorders, Prostaglandins Leukort. Essent. Fat. Acids, 71, 201, 10.1016/j.plefa.2004.03.008 · DOI · Paper page
  132. Vancassel, 2001, Plasma fatty acid levels in autistic children, Prostaglandins Leukort. Essent. Fat. Acids, 65, 1, 10.1054/plef.2001.0281 · DOI · Paper page
  133. Bent, 2014, Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in Autism, J. Am. Acad. Child. Adolesc. Psychiatry, 53, 658, 10.1016/j.jaac.2014.01.018 · DOI · Paper page
  134. Yui, 2012, Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with Autism spectrum disorders, J. Clin. Psychopharmacol., 32, 200, 10.1097/JCP.0b013e3182485791 · DOI · Paper page
  135. Voigt, 2014, Dietary docosahexaenoic acid supplementation in children with autism, J. Pediatr. Gastroenterol. Nutr., 58, 715, 10.1097/MPG.0000000000000260 · DOI · Paper page
  136. Mankad, 2015, A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism, Mol. Autism, 6, 18, 10.1186/s13229-015-0010-7 · DOI · Paper page
  137. Sheppard, 2017, Effect of Omega-3 and -6 supplementation on language in preterm toddlers exhibiting Autism spectrum disorder symptoms, J. Autism Dev. Disord., 47, 3358, 10.1007/s10803-017-3249-3 · DOI
  138. Horvath, 2017, ω-3 fatty acid supplementation does not affect Autism spectrum disorder in children: A systematic review and meta-analysis, J. Nutr., 147, 367, 10.3945/jn.116.242354 · DOI
  139. Cheng, 2019, Improving autism perinatal risk factors: A systematic review, Med. Hypotheses, 127, 26, 10.1016/j.mehy.2019.03.012 · DOI
  140. Swenne, 2012, Omega-3 essential fatty acid status is improved during nutritional rehabilitation of adolescent girls with eating disorders and weight loss, Acta Paediatr., 101, 858, 10.1111/j.1651-2227.2012.02684.x · DOI
  141. Montastier, 2012, Anorexia nervosa patients display a deficit in membrane long chain poly-unsaturated fatty acids, Clin. Nutr., 31, 386, 10.1016/j.clnu.2011.11.015 · DOI
  142. Langan, 1985, Vitamin E, vitamin A and essential fatty acid status of patients hospitalized for anorexia nervosa, Am. J. Clin. Nutr., 41, 1054, 10.1093/ajcn/41.5.1054 · doi:10.1093/ajcn/41.5.1054
  143. Sirinathsinghji, 1985, Concentration patterns of plasma dehydroepian- drosterone, delta 5-androstenediol and their sulphates, testosterone and cortisol in normal healthy women and in women with anorexia nervosa, Acta Endocrinol. (Copenh.), 108, 255
  144. Swenne, 2011, Omega-3 polyunsaturated essential fatty acids are associated with depression in adolescents with eating disorders and weight loss, Acta Paediatr., 100, 1610, 10.1111/j.1651-2227.2011.02400.x · DOI
  145. Shih, 2016, Contemporary views on the genetics of anorexia nervosa, Eur. Neuropsychopharmacol., 26, 663, 10.1016/j.euroneuro.2016.02.008 · DOI
  146. Ayton, 2004, A pilot open case series of ethyl EPA supplementation in thetreatment of anorexia nervosa, Prostaglandins Leukort. Essent. Fat. Acids, 71, 205, 10.1016/j.plefa.2004.03.007 · DOI
  147. Barbarich, 2004, Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa, Int. J. Eat. Disord., 35, 10, 10.1002/eat.10235 · DOI · Paper page
  148. Balcerzak, 2016, Polyunsaturated omega-3 fatty acids are not effective for depressive and compulsive symptoms in adolescent girls with anorexia nervosa, Eur. Neuropsychopharmacol., 26, 729, 10.1016/S0924-977X(16)31880-6 · doi:10.1016/s0924-977x(16)31880-6
  149. Woo, 2017, Acceptability and tolerability of omega-3 fatty acids as adjunctive treatment for children and adolescents with eating disorders, Eat. Disord., 25, 114, 10.1080/10640266.2016.1260379 · DOI
  150. Manos, 2018, A pilot randomized controlled trial of omega-3 fatty acid supplementation for the treatment of anxiety in adolescents with anorexia nervosa, Int. J. Eat Disord., 51, 1367, 10.1002/eat.22964 · DOI
  151. Satogami, 2019, Relationship between polyunsaturated fatty acid and eating disorders: Systematic review and meta-analysis, Prostaglandins Leukot. Essent. Fat. Acids, 142, 11, 10.1016/j.plefa.2019.01.001 · DOI
  152. Aspesi, 2017, Unblending borderline personality and bipolar disorders, J. Psychiatr. Res., 91, 90, 10.1016/j.jpsychires.2017.03.006 · DOI
  153. Gajos, 2016, The effect of omega-3 fatty acids on aggression: A meta-analysis, Neurosci. Biobehav. Rev., 69, 147, 10.1016/j.neubiorev.2016.07.017 · DOI
  154. Zaalberg, 2018, Omega-3 supplements reduce self-reported physical aggression in healthy adults, Psychiatry Res., 261, 307, 10.1016/j.psychres.2017.12.038 · DOI
  155. Choy, 2018, Omega-3 supplementation as a dietary intervention to reduce aggressive and antisocial behavior, Curr. Psychiatry Rep., 20, 32, 10.1007/s11920-018-0894-y · DOI
  156. Zanarini, 2003, Omega-3 fatty acid treatment of women with borderline personality disorder: A double blind, placebo-controlled pilot study, Am. J. Psychiatry, 160, 167, 10.1176/appi.ajp.160.1.167 · DOI · Paper page
  157. Hallahan, 2007, Omega-3 fatty acids supplementation in patients with recurrent self-harm: Single center double bind randomized controlled trial, Br. J. Psychiatry, 190, 118, 10.1192/bjp.bp.106.022707 · DOI · Paper page
  158. Bellino, 2014, Efficacy of omega-3fatty acids in the treatment of borderline personality disorder: A study of the association with valproic acid, J. Psychopharmacol., 28, 125, 10.1177/0269881113510072 · DOI
  159. Gallagher, 2017, Lipids and polyunsaturated fatty acid levels in deliberate self-harm: A 10-year follow-up study, Ir. J. Psychol. Med., 34, 117, 10.1017/ipm.2016.34 · DOI
  160. Bozzatello, 2018, Combination of omega-3 fatty acids and valproic acid in treatment of borderline personality disorder: A follow-up study, Clin. Drug Investig., 38, 367, 10.1007/s40261-017-0617-x · DOI
  161. Stoffers, 2010, Pharmacological interventions for borderline personality disorder, Cochrane Database Syst Rev., 16, CD005653
  162. Lieb, 2010, Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials, Br. J. Psychiatry, 196, 4, 10.1192/bjp.bp.108.062984 · DOI · Paper page
  163. Freeman, 2010, Complementary and alternative medicine in major depressive disorder: The American psychiatric association task force report, J. Clin. Psychiatry., 71, 669, 10.4088/JCP.10cs05959blu · DOI · Paper page
  164. European Food Safety Authority (EFSA) Panelon Dietetic Products, Nutrition and Allergies (NDA) (2012). Scientific Opinion on the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J., 10, 2815. · DOI · Paper page
  165. Yokoyama, 2007, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis, Lancet, 369, 1090, 10.1016/S0140-6736(07)60527-3 · DOI · Paper page
  166. MacLean, 2004, Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis, Evid. Rep. Technol. Assess. (Summ.), 89, 1
  167. Hartweg, 2008, Omega-3 polyunsaturated fatty acids (HUFA) for type 2 diabetes mellitus, Cochrane Database Syst. Rev., 1, CD003205
  168. Hartweg, 2009, Potential impact of omega-3 treatment on cardiovascular disease in type 2 diabetes, Curr. Opin. Lipidol., 20, 30, 10.1097/MOL.0b013e328321b3be · DOI · Paper page
  169. Bloomer, 2009, Effectt of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: A randomized, placebo controlled, cross-over study, Lipids Health Dis., 8, 36, 10.1186/1476-511X-8-36 · DOI · Paper page
  170. Freeman, 2010, Beneficial effects of omega-3 fatty acids in cardiovascular disease, J. Small Anim. Pract., 51, 462, 10.1111/j.1748-5827.2010.00968.x · DOI

Cited by

See all 73

Metadata

Authors
Bozzatello, P., Rocca, P., Mantelli, E., & Bellino, S.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2019-10-23
Volume
20
Issue
21
Pages
5257
ISSN
1422-0067 (ISSN-L)
OpenAlex
W2982007797
Cited by
73
References
37
FWCI
6.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders? https://app.cochat.ai/papers/10.3390/ijms20215257
The paper
Bozzatello, P., Rocca, P., Mantelli, E., & Bellino, S. (2019). Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders? International Journal of Molecular Sciences. https://doi.org/10.3390/ijms20215257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.